By Mill Chart
Last update: Feb 27, 2024
Consider MERCK & CO. INC. (NYSE:MRK) as a top value stock, identified by our stock screening tool. NYSE:MRK shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. Let's dive deeper into the analysis.
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NYSE:MRK has received a 7 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:MRK scores a 7 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:MRK has achieved a 5 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NYSE:MRK was assigned a score of 4 for growth:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
Our latest full fundamental report of MRK contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
MERCK & CO. INC.
NYSE:MRK (4/26/2024, 7:04:52 PM)
After market: 131.15 -0.05 (-0.04%)131.2
+0.48 (+0.37%)
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
MRK earnings call for the period ending March 31, 2024.
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Merck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda continued to dominate the treatment landscape.
Merck's bread-and-butter cancer drug grew by double digits again in the first quarter.
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.
MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.